Abstract
PCOS is a multifaceted condition characterized by ovarian abnormalities, metabolic disorders, anovulation, and hormonal imbalances. In response to the growing demand for treatments with fewer side effects, the exploration of herbal-origin drugs has gained prominence. Asparagus africanus, a traditional medicinal plant that exhibits anti-inflammatory, antioxidant, and anti-androgenic properties may have a cure for PCOS. The plant has rich biochemical profile prompted its exploration as a potential source for drug development. The aim of this study is to investigate the potential therapeutic efficacy of A. africanus in the management of PCOS through molecular docking studies with Luteinizing Hormone Receptor and Follicle-Stimulating Hormone Receptor proteins. The identified compounds underwent molecular docking against key proteins associated with PCOS, namely Luteinizing Hormone Receptor and Follicle-Stimulating Hormone Receptor. The results underscored the lead compound's superiority, demonstrating favorable pharmacokinetics, ADME characteristics, and strong molecular binding without any observed toxicity in comparison to standard drug. This study, by leveraging natural compounds sourced from A. africanus, provides valuable insights and advances towards developing more effective and safer treatments for PCOS. The findings contribute to the evolving landscape of PCOS therapeutics, emphasizing the potential of herbal-origin drugs in mitigating the complexities of this syndrome.